Testosterone Replacement Therapy: Decision-Making for Men Over 40

24 Jun Testosterone Replacement Therapy: Decision-Making for Men Over 40

As a concierge physician in Hollywood, Florida, I am asked about testosterone replacement therapy more frequently than almost any other elective treatment — and the requests come with a striking range of expectations. Some patients arrive informed, having read the clinical literature and wanting a structured clinical evaluation. Others have seen direct-to-consumer testosterone clinic advertising on social media, or have been told by a friend that TRT changed their life, and they want the same without a clear sense of what the decision actually entails.

My role is to provide neither a reflexive prescription nor a reflexive refusal, but a thorough evaluation and an honest conversation about what the evidence supports. That conversation has become significantly more nuanced in the past three years.

What Testosterone Replacement Therapy Is — And Is Not

Testosterone replacement therapy (TRT) refers to the exogenous administration of testosterone in a man whose endogenous production is clinically deficient. The key phrase is “clinically deficient” — a designation that requires both a documented biochemical deficiency (confirmed low serum testosterone on two separate morning measurements) and symptomatic burden that is attributable to that deficiency, not to other causes. This is not a performance-enhancement intervention; it is a treatment for a defined medical condition.

Symptoms commonly attributed to low testosterone include decreased libido, erectile dysfunction, diminished energy and motivation, loss of lean muscle mass, increased central adiposity, depressed mood, and impaired concentration. The challenge is that these symptoms are non-specific — they overlap substantially with depression, sleep apnea, hypothyroidism, metabolic syndrome, and burnout, all of which must be systematically excluded before attributing them to low testosterone.

The Diagnostic Framework

A proper testosterone evaluation begins with total serum testosterone, ideally drawn between 7 and 10 AM when levels peak. A single low value is insufficient; the Endocrine Society Clinical Practice Guideline recommends confirmation with a second measurement on a separate day. The lower reference limit used in most labs (generally 300–350 ng/dL) reflects the distribution of healthy young men, not a validated symptom threshold — which is why symptom correlation matters as much as the number.

Beyond total testosterone, a comprehensive hormone evaluation at our Hollywood practice includes:

• Free testosterone (calculated or measured by equilibrium dialysis), since sex hormone-binding globulin (SHBG) levels — which bind and inactivate testosterone — vary substantially among individuals
• LH and FSH to distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic)
• Prolactin, to screen for hyperprolactinemia, which suppresses the hypothalamic-pituitary-gonadal axis and requires its own workup
• Thyroid function (free T3, free T4, TSH) — hypothyroidism mimics nearly every symptom on the low-testosterone list
• Complete blood count, metabolic panel, HbA1c, and fasting lipids
• PSA — for appropriate counseling pre-TRT and as a baseline
• Hematocrit — TRT stimulates erythropoiesis; baseline hematocrit above 50 is a relative contraindication

what a true executive physical includes

The 2024 TRAVERSE Trial: What Changed

The cardiovascular safety of TRT was an open clinical question for over a decade following a 2010 trial that reported increased cardiovascular events in older men. This uncertainty deterred appropriate treatment in many candidates who would have benefited. The TRAVERSE trial — a large, placebo-controlled, randomized trial published in the New England Journal of Medicine in 2023 — addressed this directly. Among 5,246 men aged 45–80 with hypogonadism and pre-existing cardiovascular disease or elevated risk, TRT did not increase major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months.

TRAVERSE did identify a statistically significant increase in atrial fibrillation, pulmonary embolism, and acute kidney injury in the TRT group — findings that require individualized discussion, particularly for patients with pre-existing AF or hypercoagulable conditions. This is precisely the kind of nuance that a direct-to-consumer testosterone clinic running 15-minute consultations may not have time to address adequately.

Delivery Methods and Clinical Tradeoffs

Testosterone is available in several formulations, each with distinct pharmacokinetics, adherence profiles, and side effect considerations.

| Formulation | Dosing Frequency | Estradiol Conversion Risk | Practical Consideration |
|—|—|—|—|
| Topical gel (1.62%) | Daily | Moderate | Transfer risk to female partner or children; avoid skin contact 4 hrs post-application |
| Intramuscular injection (cypionate/enanthate) | Every 1–2 weeks | Higher (peak-level surges) | Requires self-injection or office visit; mood fluctuation possible near trough |
| Subcutaneous pellets | Every 3–6 months | Low-moderate | Convenient; dose not adjustable after insertion |
| Intranasal gel | Twice daily | Low | Minimal systemic absorption; less effect on erythrocytosis |
| Transdermal patch | Daily | Moderate | Skin irritation common in warm climates (relevant in South Florida) |

For many of our Broward County patients who are active outdoors — on boats, on the Broadwalk, or in the heat of a Florida summer — daily topical gel application with adequate drying time and partner-transfer awareness is the most practical initial formulation. Transdermal patches perform less reliably in humid heat, and injection protocols require consistent scheduling. Pellet insertion is popular locally but removes dose-adjustment flexibility during the first 90 days post-insertion.

Monitoring on TRT: What Good Follow-Up Looks Like

Initiating TRT without a structured monitoring protocol is a clinical error. The Endocrine Society recommends measurement of testosterone, hematocrit, PSA, and symptom assessment at 3 and 6 months after initiation, then annually thereafter. Hematocrit above 54 percent warrants dose reduction or temporary cessation; PSA elevation above 1.4 ng/mL above baseline warrants urology referral.

In a concierge setting, this monitoring cadence is not a bureaucratic checkbox. It is a real conversation — am I feeling better, are side effects present, is the dose appropriate — conducted by a physician who has continuity with the patient’s complete medical history. The direct-access model means that a patient who notices unexpected testicular atrophy (common on TRT due to suppression of endogenous LH), significant acne, or mood changes can communicate those findings the same day, not at the next available appointment six weeks away. hormone optimization longevity medicine

When TRT Is Not the Right Answer

Candidacy for TRT matters as much as the prescription. Absolute contraindications include breast or prostate cancer, polycythemia vera, uncontrolled heart failure, untreated obstructive sleep apnea, and active desire for fertility (TRT suppresses spermatogenesis). For patients in the last category — men who want to preserve fertility while addressing low testosterone — alternative approaches such as clomiphene citrate, which stimulates endogenous LH secretion, warrant consideration before exogenous testosterone is introduced.

For men whose testosterone is low-normal (350–450 ng/dL) and whose symptoms appear more consistent with sleep apnea, depression, or metabolic syndrome, treating the underlying condition first is a more principled approach than initiating TRT and hoping symptoms resolve.

The Concierge Difference in Hormone Care

Hormone optimization is an area where the concierge model’s extended appointment time and direct-access structure provide the most obvious clinical advantage. A thorough initial evaluation — history, physical examination, and laboratory review — cannot reasonably be completed in 20 minutes. The ongoing monitoring relationship requires a physician who knows the patient well enough to distinguish a therapeutic response from a placebo effect, and who will notice the subtle lab trends that warrant proactive adjustment.

If you are a man in the Hollywood or Broward County area who is evaluating testosterone replacement therapy and wants a rigorous clinical assessment rather than a rapid-access clinic prescription, Florida Concierge Medicine & Wellness welcomes your inquiry. Our approach starts with the evaluation that the decision deserves.